Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults
Viruses · 2023
DOI: 10.3390/v16010041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Christian Leli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Virology Laboratory, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
To carry out effective and quick identification of SARS-CoV-2 from nasopharyngeal swabs and contain outbreaks, reliable and rapid tools are needed. Herein, we compared a rapid antigen test based on active microfluidic technology to an RT-qPCR assay in pediatric and young adult patients admitted to the Pediatric Emergency Unit of a Children’s Hospital. Nasopharyngeal swabs collected from patients with suspected COVID-19 disease and from those without COVID-19 related symptoms, but requiring hospitalization, were performed with both antigen test and RT-qPCR assays. We included 375 patients with a median age of 5 years in the study, with an estimated overall prevalence of 7.2%. Overall, we observed a specificity of 97.4% (95% CI: 94.9–98.7) and a sensitivity of 66.6% (95% CI: 46.0–82.7) with a positive likelihood ratio (LR+) of 25.8 (95% CI: 12.8–51.8). In the subgroup of symptomatic patients, the specificity and the sensitivity were 95.2% (95% CI: 89.4–98.0) and 80.0% (95% CI: 44.2–96.5) respectively; LR+ was 16.6 (95% CI: 7.19–38.6). In the asymptomatic subset, the performance showed a specificity of 98.7% (95% CI: 95.8–99.7), a sensitivity of 58.8% (95% CI: 33.5–80.6), and an LR+ of 43.7 (95% CI: 13.3–144.0). Compared to RT-qPCR, the new microfluidic-based antigen test showed higher specificity (>95%) in the pediatric population, thus representing a suitable point-of-care testing (POCT) in a clinical setting with low prevalence of COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology and Virology Laboratory, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.
- Research and Innovation Department (DAIRI), A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.
- Pediatric and Pediatric Emergency Unit, A.O. "SS. Antonio e Biagio e C. Arrigo", Via Venezia 16, 15121 Alessandria, Italy.
ORCID-Profile: Christian Leli, Lidia Ferrara, Paolo Bottino, Iacopo Megna, Antonio Maconi
Zitieren
APA
Leli, C., Ferrara, L., Bottino, P., Bara, C., Megna, I., Penpa, S., Felici, E., Maconi, A., & Rocchetti, A. (2023). Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults. Viruses. https://doi.org/10.3390/v16010041
Vancouver
Leli C, Ferrara L, Bottino P, Bara C, Megna I, Penpa S, et al. Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults. Viruses. 2023. doi:10.3390/v16010041
BibTeX
@article{Leli2023,
author = {Leli, Christian and Ferrara, Lidia and Bottino, Paolo and Bara, Cristina and Megna, Iacopo and Penpa, Serena and Felici, Enrico and Maconi, Antonio and Rocchetti, Andrea},
title = {Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults},
journal = {Viruses},
year = {2023},
doi = {10.3390/v16010041}
}
EUVIMED